Fecal Microbiota Transplantation (FMT) in the Management of Active Ulcerative Colitis

same as above

Inclusion criteria

• Age > 18 and < 65 years
• Diagnosis of UC for > 3 months but < 5 years prior to screening as determined by the investigators
• Those with mild to moderate UC
• Those who have failed maintenance therapy with stable doses of 5-ASA, azathioprine or 6 mercaptopurine (6-MP) for > 3 months
• Where applicable, those who are taking the following medications must be at a stable dose defined as:

i) 5-ASA must be at a stable dose for 2 weeks ii) Prednisone up to 20 mg/d must be at a stable dose for 2 weeks iii) Budesonide up to 6 mg/d must be at a stable dose for 2 weeks iv) Azathioprine or 6-MP must be at a stable dose for > 8 weeks

• ability to provide informed consent
• evidence of active inflammation

Exclusion criteria

• Those whose disease is limited to the rectum (ie. proctitis)
• Those with colectomy or diverting ileostomy
• Those who are pregnancy or plan to be pregnant during the trial
• Those who are breastfeeding or plan to breast feed during the trial
• Those who are on or have previously failed a biological agent
• Those with an active infection requiring antibiotic therapy
• Those with positive stool cultures for known pathogens such as E coli, Salmonella, Shigella, Yersinia, Campylobacter, and Clostridium difficile toxin within 2 weeks of enrollment
• Those with positive CMV on colonic tissue biopsy within 2 weeks of screening
• Those with allergy to ciprofloxacin and metronidazole
• Those with colonic mucosal dysplasia